AstraZeneca Türkiye Listed by N0n Ransomware Group: Ransomware Claim — What’s Alleged & What To Do

On September 18, 2026, the ransomware group N0n listed AstraZeneca Türkiye on its leak site. The listing is an unverified accusation from the group itself. AstraZeneca Türkiye has not publicly confirmed the claim as of writing. Public detail is limited to what appears on that listing, including claims about network material and connection records and a stated threat to publish if no settlement is reached.

For patients, employees, partners, and others who deal with a major pharmaceutical operation in Türkiye, a leak-site claim matters because it raises the possibility of sensitive operational and identity-related information being used for further harm—if the claims are accurate. Nothing in the public record yet establishes that files were taken, that the volumes cited are real, or that a blackout is in force. The responsible approach is to treat the listing as a claim, watch for official statements, and take proportionate precautions.

What is being claimed

According to the N0n listing, AstraZeneca Türkiye—described in the listing in connection with pharmaceutical manufacturing (GxP) in Türkiye—has been targeted. The group claims that, if no settlement is reached, it will publish material it describes as a complete internal network-security configuration of all three sites (stated as 940 MB), covering every rule, device definition, and remote-access mapping, together with 1.35 million connection records said to relate to M365/Intune, SAP Concur, a UniFi camera estate, and internal applications. The listing also asserts that all sites are enforcing a total network blackout until settlement.

The number of people affected is unknown. Data types beyond the categories named in the listing’s own marketing language are not disclosed in a verified inventory. Timing of any intrusion, method of access, and independent confirmation of scale are undisclosed. No regulator or company statement is included in the available facts to corroborate the listing.

The group behind it: N0n

N0n is known publicly as a ransomware and extortion actor that operates a leak site to pressure organisations. Groups of this type typically claim to have stolen data, set deadlines, and threaten to release files or technical material unless payment is made. Their posts are marketing for extortion: they may exaggerate volume, recycle older material, or misattribute data. Well-documented patterns across such crews include double extortion (encryption plus leak threats), publication of sample file lists, and pressure tactics aimed at executives and customers.

For this listing specifically, only what N0n has written about AstraZeneca Türkiye can be reported: the group claims possession of network-security configuration for three sites and a large set of connection records, and it claims a network blackout pending settlement. Those statements remain the group’s claims, not confirmed findings.

AstraZeneca Türkiye and its sector

AstraZeneca Türkiye is the Turkish presence of a global biopharmaceutical company. Organisations in this sector develop, manufacture, and supply medicines under strict quality and regulatory frameworks (often discussed under GxP). They typically maintain manufacturing and quality systems, supply-chain and partner records, employee and contractor directories, clinical or medical-affairs information where applicable, and extensive IT estates spanning identity platforms, enterprise resource planning and expense tools, and physical-security systems such as cameras.

A credible compromise in this sector would be consequential because operational technology and IT configurations can aid further intrusion, and because health-adjacent and workforce data can support fraud, phishing, or privacy harm. A leak-site listing alone does not prove such a compromise occurred; it only shows that an extortion group has chosen to name the organisation.

What was likely exposed

The facts do not provide a confirmed inventory of stolen personal data. The listing names categories the group says it holds—network-security configuration across three sites and connection records tied to cloud identity and device management, expense systems, camera infrastructure, and internal applications. Exact contents are unconfirmed. Independent verification of file authenticity, completeness, or relevance to individuals is not available in the given record.

If files of the kind claimed were taken, firms in pharmaceutical manufacturing and commercial operations typically hold items such as:

• Employee and contractor identity and access records
• Business-partner, supplier, and logistics contact data
• Internal network diagrams, firewall and remote-access rules, and device inventories
• Logs or connection metadata from productivity, expense, and site-security systems
• Quality, manufacturing, or regulated-process documentation (sector-typical, not confirmed here)

None of the above should be read as a statement that those items were in fact allegedly taken from AstraZeneca Türkiye. The listing’s descriptions are the attacker’s claims.

Why it matters

If network-security configurations and remote-access mappings were genuinely obtained, they could help criminals understand how sites are segmented and how remote entry is arranged, which raises follow-on risk for the organisation and anyone whose accounts appear in related systems. If large volumes of connection records exist as claimed, they might reveal usage patterns, account identifiers, or device and location signals useful for targeted phishing or account takeover attempts.

For individuals, the practical risk is conditional: phishing that spoofs IT, HR, travel/expense, or “security incident” themes; password-reset pressure; and misuse of any personal details that might appear if corporate directories or partner lists were involved. For the organisation, reputational and regulatory attention often follows public extortion claims even when facts remain disputed. None of this establishes that AstraZeneca Türkiye failed in any specific control; a leak-site post does not, by itself, prove negligence or confirm what was accessed.

What a leak-site listing does establish is narrow: a named group has publicly associated this company with an extortion narrative and has described material it says it will publish. What it does not establish is theft, accuracy of volumes, blackout status, or impact on any named person.

Steps worth taking either way

Because the incident is unconfirmed, steps should be proportionate and useful whether or not the claims prove true. If you work with or receive mail from AstraZeneca Türkiye or related partners, treat unexpected messages about breaches, passwords, invoices, or urgent “settlement” or IT blackout themes with caution. Prefer official channels you already trust. Use unique passwords and multi-factor authentication on email and work accounts. Monitor bank and credit activity if you have shared financial or expense data with corporate systems in this ecosystem. If you are an employee or contractor, follow only guidance issued through verified internal channels when it appears.

Readers can run a free exposure scan of their email to check whether their information has already surfaced in known breach data sets unrelated to this claim. Remain alert for official company or regulator updates; until those exist, the N0n listing should be read as an allegation, not as settled fact.

AICompiled with AI assistance from public sources and published under our editorial standards.